Increased serum levels of advanced glycation endproducts (AGEs) shown to predict total, cardiovascular disease and coronary mortality in women with type 2 diabetes
Document Actions
Advanced glycation endproducts (AGEs) are formed by glycation or glycoxidation of proteins and lipids in the presence of physiological or pathological levels of ambient glucose, and have been linked to premature atherosclerosis in patients with diabetes. To assess whether increased serum levels of AGEs predict total, cardiovascular disease (CVD) and coronary heart disease (CHD) mortality, serum levels of AGEs were determined by immunoassay in a random sample of 874 Finnish subjects from a population-based study. These study participants were then followed during 18 years for total, CVD and CHD mortality. Using multivariate Cox regression analysis, AGEs were significantly associated with total (P=0.002) and CVD mortality (P=0.021) in women, but not men. Even after adjusting for confounding factors such as high-sensitivity C-reactive protein, serum levels of AGEs in the highest sex-specific quartile predicted all-cause (HR=1.51), CVD (HR=1.56), and CHD (HR=1.68) mortality in women. AGEs levels may therefore represent an additional CVD risk marker in women.
Abstract
